TLDR Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
A 48-year-old woman with idiopathic twenty-nail dystrophy (TND) was successfully treated with Upadacitinib, a second-generation selective JAK1 inhibitor, marking the first documented case of its use for this condition. The patient, who experienced severe pain from local injection therapy, showed remarkable improvement in nail appearance after 6 months of oral Upadacitinib at 15 mg daily, with no adverse reactions. This case suggests that Upadacitinib could be a promising treatment for TND, especially for patients intolerant to painful local treatments.
41 citations
,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
10 citations
,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
70 citations
,
October 2020 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
September 2025 in “Australasian Journal of Dermatology” New medications could improve treatment for severe alopecia areata in Australia.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
